CN114949123B - Composition, and preparation method and application thereof - Google Patents

Composition, and preparation method and application thereof Download PDF

Info

Publication number
CN114949123B
CN114949123B CN202210589300.2A CN202210589300A CN114949123B CN 114949123 B CN114949123 B CN 114949123B CN 202210589300 A CN202210589300 A CN 202210589300A CN 114949123 B CN114949123 B CN 114949123B
Authority
CN
China
Prior art keywords
parts
powder
composition
uric acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210589300.2A
Other languages
Chinese (zh)
Other versions
CN114949123A (en
Inventor
王磊
黄燕巧
薛强
程鑫颖
吴利苹
冯雪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chenguang Biotech Group Handan Co ltd
Original Assignee
Chenguang Biotech Group Handan Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chenguang Biotech Group Handan Co ltd filed Critical Chenguang Biotech Group Handan Co ltd
Priority to CN202210589300.2A priority Critical patent/CN114949123B/en
Publication of CN114949123A publication Critical patent/CN114949123A/en
Application granted granted Critical
Publication of CN114949123B publication Critical patent/CN114949123B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a composition, a preparation method and application thereof. The composition comprises soybean lecithin, inulin, hawthorn powder, fructo-oligosaccharide, green tea powder, tea polyphenol, red rice powder, alfalfa powder, lotus leaf powder, kudzuvine root powder, mulberry leaf powder and vitamin C, and also comprises roxburgh rose powder, lophatherum gracile powder and cyclocarya paliurus leaf powder. The composition can realize the effect of preventing and/or assisting in treating hyperuricemia and hyperlipidemia, and is safe and effective and free from toxic and side effects.

Description

Composition, and preparation method and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a composition and a preparation method and application thereof.
Background
Hyperuricemia is a disease in which blood uric acid exceeds a normal value due to a disorder of purine metabolism and/or a disorder of uric acid excretion, and does not manifest any symptoms clinically in the early stage. In the case of hyperuricemia for a long period of time, uric acid can precipitate in the form of sodium salt in joints, soft tissues, cartilage and kidneys, cause lesions of organs and tissues of the human body, cause gout, and cause serious complications including gouty arthritis, gouty nephropathy and the like. Therefore, how to effectively reduce uric acid is a major problem facing hyperuricemia patients and gout patients.
Hyperlipidemia is a systemic disease and can be divided into two major categories, primary hyperlipidemia and secondary hyperlipidemia, according to the cause of the disease. The lesions are hidden, progressive and systemic to the body. The direct damage of the medicine is accelerating systemic atherosclerosis, and a large amount of research data show that hyperlipidemia is an independent and important risk factor for cerebral apoplexy, coronary heart disease, myocardial infarction and sudden cardiac death. Hyperuricemia and primary gout are obviously and positively correlated with diseases such as obesity, hyperlipidemia, diabetes, atherosclerosis and the like. From the clinical practice, most gout patients have higher blood uric acid level and higher blood lipid level.
The existing medicines for treating hyperuricemia mainly comprise febuxostat, allopurinol, colchicine, benzbromarone and the like, and the medicines for treating hyperlipoidemia mainly comprise statin, fibrate and the like. The medicines have better curative effect, but the medicines are easy to produce antagonism when taken simultaneously, and in addition, the medicines show certain toxic and side effects in clinic, and the long-term use of the medicines brings great health hidden trouble to patients. Under the situation, searching a safer and more effective way for reducing uric acid and blood fat from raw materials is one of the directions for preventing and treating gout, hyperuricemia and hyperlipidemia.
The Chinese patent application (patent application No. 201911313891.5) discloses a solid drink of alfalfa tea and a preparation method thereof, relates to the technical field of solid drinks, and claims that the solid drink has the functions of assisting in reducing blood pressure and blood fat, but has no efficacy test and human body trial, can verify the claimed efficacy, and does not give a teaching or suggestion that the scheme of the solid drink can be expected to realize uric acid reduction. Therefore, further investigation of the formulation is necessary.
Disclosure of Invention
Aiming at the problems of the prior art, the invention overcomes the defects of high cost and large side effect of the prior treatment method, and one of the purposes of the invention is to provide a composition with uric acid and blood lipid reducing effects.
In order to achieve the object, the technical scheme of the invention is as follows:
a composition comprises soybean phospholipid, inulin, fructus crataegi powder, fructo-oligosaccharide, green tea powder, tea polyphenols, red rice powder, herba Medicaginis powder, folium Nelumbinis powder, radix Puerariae powder, folium Mori powder and vitamin C, and further comprises fructus Rosae Normalis powder, herba Lophatheri powder and cyclocarya paliurus powder.
The soybean lecithin and the red rice have the effects of obviously reducing cholesterol, triglyceride and low-density lipoprotein in blood, and can prevent cardiovascular and cerebrovascular diseases and improve hyperlipidemia.
Fructo-oligosaccharides and inulin both belong to prebiotics and are also water-soluble dietary fibers. The fructo-oligosaccharide can improve intestinal flora and stimulate intestinal peristalsis, most patients with hyperlipidemia and gout are accompanied with metabolic syndrome, and the dietary fiber can be supplemented to improve the metabolic syndrome, so that the overall metabolic condition of the patients is improved.
Hawthorn fruit is sour, sweet and slightly warm in nature and enters spleen, stomach and liver meridians. Fructus crataegi contains flavone, triterpene, flavane polymer and rutin, and has effects in resolving food stagnation, invigorating stomach, promoting qi circulation, dispelling blood stasis, increasing coronary flow, and reducing blood lipid and blood cholesterol concentration.
The tea polyphenol in the green tea can comprehensively regulate blood fat, and especially reduce the contents of serum TG, TC and low-density lipoprotein cholesterol. Puerarin in radix Puerariae can inhibit xanthine oxidase, promote uric acid excretion, and reduce serum uric acid level to achieve anti-gout effect. Fructus Rosae Normalis and herba Medicaginis are rich in flavonoids and polyphenols, and have effects of preventing and treating atherosclerosis and enhancing immunity, and has remarkable lipid lowering effect.
The lotus leaf contains a plurality of alkaloid substances such as nuciferine, lotus alkaloid and the like, and components such as flavone, polysaccharide, vitamin and the like, and has the effects of clearing summer heat, reducing blood pressure, reducing the content of triglyceride and cholesterol in serum and the like. Nuciferine and analogues thereof can reduce serum uric acid level, especially uric acid level caused by elevated uric acid level due to consumption of hypoxanthine and nicotinic acid, and can effectively relieve hyperuricemia.
The mulberry leaf contains various active ingredients such as vitamins, flavone, polyphenol, alkaloid, terpenoid, steroid and the like, and has various functions of reducing blood sugar, blood pressure, cholesterol, atherosclerosis resistance, uric acid reduction, gout prevention and treatment and the like. Cyclocarya paliurus has various functions of reducing blood, blood lipid, blood pressure, blood sugar, and oxygen.
The research shows that the components with various prevention and control/ventilation effects, namely fructo-oligosaccharide, inulin, kudzuvine root, lotus leaf and mulberry leaf, in the known formula cannot actually exert ideal uric acid reducing effect, but unexpectedly have double effects of reducing blood fat and reducing uric acid when the roxburgh rose powder, the lophatherum gracile powder and the cyclocarya paliurus leaf powder which have no obvious uric acid reducing effect are compounded in a specific formula for use. And inulin in the formula of the invention also plays a role in cooperation with other components, thereby playing the roles of further reducing uric acid and blood fat. The invention integrally expands the effect of the composition and avoids the side effect of the traditional western medicines.
The composition combines soybean phospholipids, composite prebiotics and various raw materials simultaneously, can improve the internal environment and intestinal metabolism capacity of a human body, has the effects of enhancing heat clearing and dampness removing, reducing phlegm and clearing heat, promoting diuresis and softening hard masses, clearing heat and dredging collaterals, balancing yin and yang, improving body excretion and other functions, can reduce blood fat and promote purine to be discharged out of the human body along with urine, comprehensively regulates the uric acid concentration of blood, and has good effects of reducing uric acid and preventing gout.
The invention combines various plant essences, is rich in terpenes, flavonoids and phenolic acid compounds, can remove cholesterol and fat in human blood, reduces uric acid and blood fat by reducing the enzyme activities of fatty acid synthase, xanthine oxidase and the like, and has the functions of supplementing and supplementing the functional components contained in the raw materials in the human body, and has the synergistic effect.
Preferably, the mass ratio of the roxburgh rose powder, the lophatherum gracile powder and the cyclocarya paliurus leaf powder is (4-6.5): (3-7): (2.5-6).
More preferably, the mass ratio of the roxburgh rose powder to the lophatherum gracile powder to the cyclocarya paliurus leaf powder is 6.5:7:6, so that better uric acid and lipid lowering effects are obtained.
The composition of the invention comprises the following components in parts by weight:
10-35 parts of soybean lecithin, 5-30 parts of inulin, 5-20 parts of hawthorn powder, 5-20 parts of fructo-oligosaccharide, 2-8 parts of green tea powder, 1-8 parts of tea polyphenol, 4-6.5 parts of roxburgh rose powder, 2-8 parts of red yeast rice powder, 1.5-10 parts of alfalfa powder, 1-10 parts of lotus leaf powder, 2-15 parts of kudzuvine root powder, 1-10 parts of mulberry leaf powder, 3-7 parts of lophatherum gracile powder, 2.5-6 parts of cyclocarya paliurus leaf powder and 0.1-1.5 parts of vitamin C;
preferably, the composition comprises the following components in parts by weight:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of lophatherum gracile powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
The composition of the present invention further comprises a sweetener, a glidant, and an anticaking agent.
Preferably, the sweetener is steviol glycoside, the glidant is silicon dioxide, and the anticaking agent is microcrystalline cellulose.
The composition of the invention comprises the following components in parts by weight: 0.1-0.3 part of sweetener, 0.1-2 parts of glidant and 3-13 parts of anticaking agent.
The invention further provides a method for preparing the composition, which comprises the step of mixing the components.
As a specific embodiment, a method for preparing a composition of the present invention comprises the steps of:
s1: weighing soybean phospholipid, inulin, hawthorn powder, fructo-oligosaccharide, green tea powder, tea polyphenol, roxburgh rose powder, red rice powder, alfalfa powder, lotus leaf powder, kudzuvine root powder, mulberry leaf powder, lophatherum gracile powder, cyclocarya paliurus leaf powder, vitamin C, microcrystalline cellulose, silicon dioxide and stevioside according to the weight ratio.
S2: putting the weighed materials into equipment, fully stirring and mixing for 15-25min, and uniformly mixing.
S3: and quantitatively split charging the stirred materials by an automatic filling machine. Or adding other edible adjuvants and making into tablet, granule or capsule.
The invention also provides application of the composition in preparation of uric acid and/or blood lipid lowering products.
In the invention, the product is a traditional Chinese medicine preparation; preferably, the dosage form of the product is a tablet, granule or capsule;
and/or the product further comprises edible adjuvants (which can be produced by conventional production processes).
The powder prepared by the formula has the advantages of stable property, convenient storage and carrying, rich sour and sweet taste, high bioavailability, wide audience and the like, and has good development and application prospects.
The invention has the advantages that:
the invention provides a composition with the effects of reducing uric acid and reducing blood fat, and further can prevent and/or assist in treating hyperuricemia and hyperlipidemia. The composition can relieve the symptoms of gout and hyperlipidemia through specific raw material proportions, has the effects of inducing diuresis to alleviate edema, clearing liver and promoting gallbladder, is safe and free of toxic and side effects, is favorable for preventing and relieving various symptoms caused by high uric acid and blood lipid, can be used for a long time, has rich mouthfeel, is wide in audience, and has good development and application prospects.
Detailed Description
Preferred embodiments of the present invention will be described in detail below with reference to examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention may be made by those skilled in the art without departing from the spirit and scope of this invention.
The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents and the like used in the examples below, unless otherwise indicated, are all those available commercially or may be prepared by methods conventional in the art.
Example 1
The embodiment provides a composition with uric acid and blood fat reducing effects, which comprises the following raw materials in parts by weight: 10 parts of soybean lecithin, 5 parts of inulin, 5 parts of hawthorn powder, 5 parts of fructo-oligosaccharide, 2 parts of green tea powder, 1 part of tea polyphenol, 4 parts of roxburgh rose powder, 2 parts of red rice powder, 1.5 parts of alfalfa powder, 1 part of lotus leaf powder, 2 parts of kudzuvine root powder, 1 part of mulberry leaf powder, 3 parts of lophatherum gracile powder, 2.5 parts of cyclocarya paliurus leaf powder, 0.1 part of vitamin C powder, 0.1 part of stevioside, 0.1 part of silicon dioxide and 3 parts of microcrystalline cellulose.
The preparation method of the composition with the effects of reducing uric acid and reducing blood fat comprises the following steps:
s1: weighing the raw materials of the composition according to the weight portion.
S2: the weighed materials are put into equipment and fully stirred and uniformly mixed.
S3: and quantitatively split charging the stirred materials by an automatic filling machine to prepare the composition with the uric acid and blood fat reducing effect.
Example 2
The embodiment provides a composition of the invention, which comprises the following components in parts by weight: 20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of lophatherum gracile powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
The preparation is described in example 1.
Example 3
The embodiment provides a composition of the invention, which comprises the following components in parts by weight: 35 parts of soybean lecithin, 30 parts of inulin, 20 parts of hawthorn powder, 20 parts of fructo-oligosaccharide, 8 parts of green tea powder, 8 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 8 parts of red rice powder, 10 parts of alfalfa powder, 10 parts of lotus leaf powder, 15 parts of kudzuvine root powder, 10 parts of mulberry leaf powder, 7 parts of lophatherum gracile powder, 6 parts of cyclocarya paliurus leaf powder, 1.5 parts of vitamin C, 0.3 part of stevioside, 2 parts of silicon dioxide and 13 parts of microcrystalline cellulose.
The preparation is described in example 1.
Comparative example 1
The comparative example was prepared by using 12 kinds of active ingredients described in "a soybean lecithin red yeast rice alfalfa tea solid beverage and its preparation method (patent application number: 201911313891.5)" in chinese patent application, and using the formulation and method of example 2 of the present invention.
The specific formula is as follows:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6 parts of red rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 0.4 part of vitamin C powder, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
Comparative example 2
This comparative example provides a composition which is substantially the same as the formulation and preparation method of example 2 except that the addition amounts of 3 components of roxburgh rose powder, lophatherum gracile powder and cyclocarya paliurus powder in the formulation are changed to 6.5 parts, 2.5 parts, 2 parts in order, and the other components and the ratio are kept unchanged.
Comparative example 3
This comparative example provides a composition which is substantially the same as the formulation and preparation method of example 2 except that the addition amounts of 3 components of roxburgh rose powder, lophatherum gracile powder and cyclocarya paliurus powder in the formulation are changed to 7.5 parts, 2.5 parts, 8 parts in order, and the other components and the ratio are kept unchanged.
Comparative example 4
This comparative example provides a composition that is substantially identical to the formulation and preparation method of example 1, except that cyclocarya paliurus powder is not added to the formulation, and other components and proportions remain the same as in example 1.
Comparative example 5
This comparative example provides a composition which is substantially identical to the formulation and preparation method of example 1, except that cyclocarya paliurus leaf powder and lophatherum gracile powder are not added to the formulation, and other components and proportions remain the same as in example 1.
Comparative example 6
This comparative example provides a product whose composition is only a sample of roxburgh rose powder.
Comparative example 7
This comparative example provides a product whose composition is only a sample of lophatherum gracile powder.
Comparative example 8
This comparative example provides a product whose composition is only cyclocarya paliurus powder sample.
Comparative example 9
This comparative example provides a composition which is substantially identical to the formulation and preparation of example 2, except that no inulin is added to the formulation and the other components and proportions remain the same as in example 2.
Comparative example 10
This comparative example provides a composition which is substantially identical to the formulation and preparation method of example 1, except that no mulberry leaf powder is added to the formulation, and the other components and proportions remain the same as in example 1.
Comparative example 11
This comparative example provides a composition prepared according to the method of example 1 of patent application No. 201911313891.5.
Experimental example 1 animal efficacy validation test
This experimental example tests the effect of the products obtained by the preparation of the above examples and comparative examples. The method comprises the following steps:
establishing a pre-test experimental animal by using a hyperuricemia model: SD rats, male, 6-8 weeks old, 200+ -20 g,20, purchased from St Bei Fu (Beijing) Biotechnology Co., ltd., license number: SCXK (jing) 2019-0010; maintaining the feed and the padding.
The experimental animals are adapted: SPF-class male SD rats, 20, weight 180-220g, experimental animal feeding environment: the temperature is 20-26 ℃, the humidity is 40-70%, the light and the dark are alternately carried out every day for 12 hours, and animals drink water freely. And (5) placing the seeds into a quarantine room to be suitable for 7d of feeding. The rats fed adaptively for 7d are randomly divided into a blank group, a model 1 group, a model 2 group and a model 3 group according to the weight.
Evaluation of uric acid lowering efficacy of samples from each group of experiments (examples and comparative examples) formal test animals: SD rats, male, 6-8 weeks old, 200+ -20 g,80, were fed for 7d under the same conditions as described above for the pre-experiment of hyperuricemia model establishment, and were randomly divided into 5 groups of blank group, model group, examples 1-3, and comparative examples 1-11 according to body weight.
The rat kidney function index and blood lipid process detection method comprises the following steps: after each group of experimental rats starts to be dosed, the experimental rats are subjected to fundus venous plexus blood collection on the 30d day of dosing, a plasma sample is placed at room temperature for 1-2h, the blood is centrifuged at 4 ℃ for 10min (215 xg) to obtain serum, the change condition of uric acid content in the serum is measured by a biochemical analyzer, and the change condition of creatinine, total cholesterol and triglyceride in the serum is detected by a biochemical kit.
Other index detection methods of hyperuricemia rats: liver XOD, ADA viability assay: after 30d of dosing, after anaesthetizing and killing the rats, the liver tissue of the rats was accurately weighed in mass (g): volume (mL) was calculated as 1:9 proportion of 0.9% physiological saline solution, mechanically homogenizing in ice water bath, centrifuging at 4deg.C (10 min,215 Xg), collecting supernatant, and measuring. XOD and ADA viability in liver tissue was determined using a biochemical analyzer.
Hyperuricemia rat molding: reference (1) Chen Linjun, yang, wu Di, etc. establishment of rat model for hyperuricemia and complications thereof [ J ]. Protect on Chinese laboratory animals, 2020,28 (4): 510-516.[2] Dan Hui, liang Xiaoshan, huang Liwen, etc. A modified and effect evaluation study of rat model induction method for hyperuricemia [ J ]. J.J.application Physiol, 2020,36 (3): 223-227.), adenine and potassium oxazinate were selected as modeling agents, pre-experiments were designed, and the administration amount and modeling time of modeling agents were searched, and the groups and administration conditions of the pre-experimental laboratory animals are shown in Table 1.
TABLE 1
Test data and analysis:
the change of uric acid and urea levels of rats during the administration process is shown in Table 2, and after the 7 th day of administration, the uric acid and urea levels of rats in each model group are increased compared with that of the blank group, but the uric acid and urea levels are not significant (P is less than 0.05); after the 14 th day of administration, uric acid and urea levels in the low and medium dose groups were significantly increased (P < 0.05) compared to the blank group; after 35 days of administration, uric acid levels were still significantly elevated (P < 0.05) in rats from each model group compared to the blank group.
TABLE 2
In the table, "x" indicates that significant P < 0.05 was found in the blank group.
Based on the results of the preliminary experiments, it was confirmed that the molding mode was to use adenine (the amount of administration was 100 mg/kg. BW. D) and potassium oxazinate (the amount of administration was 500 mg/kg. BW. D) for 14 days in combination, and then the gastric lavage administration was started after the molding was successful. The mode of administration of each group of experimental rats is shown in Table 3.
TABLE 3 Table 3
Test data and analysis:
the change of the kidney function index of the rats is shown in Table 4. Compared with a blank group, the uric acid and creatinine level of a rat in the model group is obviously increased (P is less than 0.05), which indicates that the high uric acid model of the rat is successfully constructed, the uric acid in the model group is obviously reduced (P is less than 0.05) compared with the uric acid in the example 1, the example 2 and the example 3 after the rat is administrated for 30 days, the creatinine in the model group is obviously reduced (P is less than 0.05), which indicates that the composition has obvious uric acid reducing effect, and the components are combined to have synergistic effect on uric acid reducing. The uric acid in comparative examples 1, 2, 3, 4 and 5 is reduced, but the uric acid is not significant, which indicates that the roxburgh rose powder, the lophatherum gracile powder and the cyclocarya paliurus leaf powder can only play a role in reducing uric acid under specific matching. The uric acid in comparative examples 6, 7 and 8 is not reduced, which indicates that the roxburgh rose powder, the lophatherum gracile powder and the cyclocarya paliurus leaf powder can not reduce uric acid when being used alone. The comparative examples 9, 10 and 11 all have reduced but no significant difference, which shows that the matching of inulin and mulberry leaf powder with other components in the composition also plays a role in ensuring uric acid reducing effect.
TABLE 4 Table 4
In the table, "×" indicates significant P < 0.05 with the blank group, and "#" indicates significant P < 0.05 with the model group.
The changes of the rat adenosine deaminase and xanthine oxidase are shown in table 5, and the data show that the composition can realize the regulation of the rat with high uric acid by regulating the activity of ADA and XOD enzymes. The adenosine deaminase and xanthine oxidase activities of the model group were significantly increased (P < 0.05) compared to the blank group, and the adenosine deaminase activities and xanthine oxidase activities of examples 1, 2 and 3 were significantly decreased (P < 0.05) compared to the model group. Whereas the adenosine deaminase and xanthine oxidase activities of comparative examples 1, 2, 3, 5, 6, 7, 9, 10, 11 were reduced but not significantly different from the model group. The comparative examples 4 and 8 were poor in use effect.
TABLE 5
In the table, "×" indicates significant P < 0.05 with the blank group, and "#" indicates significant P < 0.05 with the model group.
The changes in total cholesterol and triglyceride levels in rats are shown in Table 6. Compared with a blank group, the total cholesterol and triglyceride content of a rat in the model group is obviously increased (P is less than 0.05), which indicates that the hyperlipoidemia model of the rat is successfully constructed, the TC content of the embodiment 1, the embodiment 2 and the embodiment 3 is obviously reduced compared with that of the model group (P is less than 0.05), the TC content of the embodiment 1-11 is not obviously reduced, the TG content of the embodiment 1, the embodiment 2 and the embodiment 3 is obviously reduced compared with that of the model group (P is less than 0.05), and the rest of the embodiment 1-11 is not obviously different compared with that of the model group, so that the composition has the effect of obviously reducing the total cholesterol and triglyceride in blood of the hyperlipoidemia rat under the specific component combination proportion.
TABLE 6
Group of Total cholesterol content (TC) Triglyceride content (TG)
Blank group 3.04±0.18 1.19±0.14
Model group 5.23±0.42* 1.64±0.31*
Example 1 4.31±0.25# 1.30±0.09#
Example 2 4.01±0.32# 1.28±0.23#
Example 3 4.28±0.31# 1.34±0.19#
Comparative example 1 4.84±0.23 1.66±0.57
Comparative example 2 4.78±0.42 1.59±0.26
Comparative example 3 4.49±0.18 1.51±0.24
Comparative example 4 4.78±0.42 1.56±0.31
Comparative example 5 4.85±0.22 1.48±0.23
Comparative example 6 5.12±0.38 1.60±0.23
Comparative example 7 5.20±0.25 1.59±0.57
Comparative example 8 5.15±0.36 1.59±0.48
Comparative example 9 4.61±0.15 1.56±0.57
Comparative example 10 4.52±0.12 1.55±0.23
Comparative example 11 5.13±0.31 1.51±0.44
In the table, "×" indicates significant P < 0.05 with the blank group, and "#" indicates significant P < 0.05 with the model group.
Human body trial test:
the composition prepared in example 2 was used as a sample for product trial for 20 patients with hyperlipidemia and hyperuricemia (triglyceride higher than 2mmoL/L, blood uric acid detection value higher than 450. Mu. Mole/L).
The trial method comprises the following steps: 1 dose of the medicine is taken with warm water each time, 15g of the medicine is taken each time in the morning and evening for 45 days. During the administration period, enough water is used to limit the intake of high-purine foods such as animal viscera, seafood and the like, and no drinking or spicy and irritating foods are used.
And (3) observing the indexes: changes in the uric acid level and triglyceride level of the blood of the patient were observed before and after administration for 45 days.
The average values of the uric acid level and the triglyceride level in the blood of the patients before and after administration are shown in Table 7. Wherein, after 20 testers continuously test for 45 days, the uric acid level of blood is recovered to a normal value, and 18 cases of triglyceride level recovery normal values exist. The effective rate of uric acid reduction (the proportion of testers recovering normal values is 100 percent and the effective rate of blood fat reduction is 90 percent) is tested, and the symptoms of joint pain caused by hyperuricemia are relieved after the composition is fed back by the testers. No allergic or other adverse reactions were observed during the trial.
TABLE 7
The human body trial shows that the composition provided by the invention has the effect of reducing uric acid and triglyceride, and has a good effect on adjuvant therapy of hyperlipidemia and gout.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.

Claims (12)

1. The composition with uric acid reducing effect is characterized by comprising the following components in parts by weight: 10-35 parts of soybean lecithin, 5-30 parts of inulin, 5-20 parts of hawthorn powder, 5-20 parts of fructo-oligosaccharide, 2-8 parts of green tea powder, 1-8 parts of tea polyphenol, 4-6.5 parts of roxburgh rose powder, 2-8 parts of red yeast rice powder, 1.5-10 parts of alfalfa powder, 1-10 parts of lotus leaf powder, 2-15 parts of kudzuvine root powder, 1-10 parts of mulberry leaf powder, 3-7 parts of lophatherum gracile powder, 2.5-6 parts of cyclocarya paliurus leaf powder and 0.1-1.5 parts of vitamin C.
2. The composition according to claim 1, wherein the mass ratio of the roxburgh rose powder, the lophatherum gracile powder and the cyclocarya paliurus leaf powder is 6.5:7:6.
3. The composition according to claim 1, characterized by comprising, in parts by weight:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of lophatherum gracile powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
4. A composition according to any one of claims 1 to 3, further comprising a sweetener, a glidant and an anticaking agent.
5. The composition of claim 4, wherein the sweetener is steviol glycoside, the glidant is silicon dioxide, and the anticaking agent is microcrystalline cellulose.
6. The composition according to claim 4, comprising, in parts by weight: 0.1-0.3 part of sweetener, 0.1-2 parts of glidant and 3-13 parts of anticaking agent.
7. The composition according to claim 5, comprising, in parts by weight: 0.1-0.3 part of sweetener, 0.1-2 parts of glidant and 3-13 parts of anticaking agent.
8. A method of preparing the composition of any of claims 1-7, comprising the step of mixing the components.
9. Use of a composition according to any one of claims 1 to 7 for the preparation of uric acid lowering products.
10. Use of a composition according to any one of claims 1 to 7 for the preparation of a hypolipidemic product.
11. The use according to claim 9 or 10, wherein the product is a Chinese medicinal preparation.
12. The use according to claim 11, wherein the product is in the form of a tablet, granule or capsule.
CN202210589300.2A 2022-05-26 2022-05-26 Composition, and preparation method and application thereof Active CN114949123B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210589300.2A CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210589300.2A CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114949123A CN114949123A (en) 2022-08-30
CN114949123B true CN114949123B (en) 2024-02-06

Family

ID=82956406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210589300.2A Active CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114949123B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050324A (en) * 2017-01-26 2017-08-18 赵杏珍 A kind of integration of drinking and medicinal herbs Chinese medicine function health toxin expelling drink for preventing and treating gout and three high drop
CN110959710A (en) * 2019-12-19 2020-04-07 米昌锋 Soybean lecithin red yeast rice alfalfa tea solid beverage and preparation method thereof
CN113142352A (en) * 2021-04-08 2021-07-23 贵州贝因特生物技术有限公司 Preparation method of roxburgh rose and cyclocarya paliurus instant tea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050324A (en) * 2017-01-26 2017-08-18 赵杏珍 A kind of integration of drinking and medicinal herbs Chinese medicine function health toxin expelling drink for preventing and treating gout and three high drop
CN110959710A (en) * 2019-12-19 2020-04-07 米昌锋 Soybean lecithin red yeast rice alfalfa tea solid beverage and preparation method thereof
CN113142352A (en) * 2021-04-08 2021-07-23 贵州贝因特生物技术有限公司 Preparation method of roxburgh rose and cyclocarya paliurus instant tea

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
淡竹叶化学成分与药理作用研究进展;陈烨;《亚太传统医药》;第10卷(第13期);50-52 *

Also Published As

Publication number Publication date
CN114949123A (en) 2022-08-30

Similar Documents

Publication Publication Date Title
CN102670864B (en) Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes
CN107319525A (en) One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof
US20130131025A1 (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and food or beverage
CN109924511A (en) A kind of composition and preparation method of containing water soluble dietary fiber and insoluble diedairy fiber
CN106103696A (en) Novel plan lactobacillus casei bacterial strain
CN106667915A (en) Baicalin-aluminum dry suspension for treating pigling diarrhoea
CN110075216B (en) Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof
WO2013087023A1 (en) Natural weight reduction health composition and application thereof
CN105055855B (en) With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application
CN109620948A (en) The full nature cell Opsonizing method of high lithemia/gout
CN109170916A (en) One kind keeps fit and healthy food compositions and preparation method thereof
CN114949123B (en) Composition, and preparation method and application thereof
CN112826889A (en) Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease
CN1839702A (en) Compound Gynostemma pentaphylla tea for assisting invigorating brain and heart and its preparation method
JPH0769902A (en) Magnesium replenishing material
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
CN102596214B (en) Composition for alleviating fatty liver
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN106490614A (en) A kind of composition and its application as diabetes full nutrition formula food
KR20010103065A (en) Diet composition comprising dietary fiber
WO2005041995A1 (en) α-GLUCOSIDASE ACTIVITY INHIBITOR
CN105639620A (en) Health food composition for increasing bone mineral density, and preparation method thereof
CN107073032A (en) Kidney failure progression inhibitors, prophylactic agent for renal failure and indoxyl sulfate produce inhibitor
CN105166901B (en) A kind of dialysis patient alimentation composition
TWI745667B (en) A soybean protein isolate is used to prepare a composition for preventing or treating osteoporosis complicated with sarcopenia, improving physical function and reducing fatigue after exercise.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant